Intraventricular Viral Vector Delivery for Spinal Cord Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating disorders affecting motor function, particularly those related to the brain and spinal cord, are inadequate in effectively delivering therapeutic agents to the spinal cord, limiting the treatment of motor neuron disorders such as ALS.
Innovation Solution
Intraventricular administration of recombinant neurotrophic viral vectors containing transgenes like IGF-1, VEGF, and others, which favor expression in ependymal cells, to deliver therapeutic agents directly to the spinal cord and brainstem, promoting motor function recovery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to deliver therapeutic agents to the spinal cord, then the treatment approach is simple, but the delivery effectiveness to the spinal cord is insufficient
Solution Approach 1:
The patent uses ependymal cells as intermediary carriers to deliver therapeutic transgene products to the spinal cord. The viral vector first transduces ependymal cells lining the ventricles, which then express and distribute the therapeutic protein throughout the CNS via cerebrospinal fluid circulation, achieving reliable spinal cord delivery without direct injection into the cord
Solution Approach 2:
The patent shifts the delivery approach from direct spinal cord injection to intraventricular injection, utilizing the three-dimensional cerebrospinal fluid circulation system to distribute the therapeutic agent throughout the CNS. This dimensional change allows broader distribution and more reliable delivery to multiple spinal cord regions simultaneously
2Reliability
If intraventricular administration of viral vectors is used, then therapeutic agents are delivered effectively to the spinal cord, but the method complexity increases
Solution Approach 1:
The ependymal cells serve as self-service delivery vehicles by naturally expressing the therapeutic transgene product and distributing it through their physiological function of lining the ventricles and interacting with cerebrospinal fluid. This eliminates the need for complex direct spinal cord injection procedures while achieving reliable therapeutic delivery
Solution Approach 2:
The intraventricular viral vector administration provides multi-functional benefits: it delivers the therapeutic transgene to ependymal cells, utilizes the existing cerebrospinal fluid circulation system for distribution, and achieves broad CNS coverage including the spinal cord. This single administration method accomplishes multiple delivery objectives simultaneously
3Reliability
If therapeutic proteins are delivered throughout the CNS, then motor function improves and disease progression slows, but the treatment complexity increases
Solution Approach 1:
The patent employs ependymal cells as intermediary factories that produce and release therapeutic proteins into the cerebrospinal fluid, which then distributes these proteins throughout the CNS. This intermediary approach achieves broad therapeutic coverage and functional improvement without requiring complex multi-site injections or direct brain/spinal cord interventions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly extends lifespan, improves motor function, reduces astrogliosis, and slows disease progression in ALS models by delivering therapeutic proteins throughout the CNS, demonstrating therapeutic efficacy in treating motor neuron disorders.
Implementation Method 1
The neurons internalize the AAV vector and transport it in a retrograde manner along the axon to the cell body
Implementation Method 2
Cells transduced by AAV vectors may express a therapeutic transgene product, such as an enzyme or a neurotrophic factor, to mediate beneficial effects intracellularly. These cells may also secrete the therapeutic transgene product, which may be subsequently taken up by distal cells where it may mediate its beneficial effects
Data Source
AI summary
This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention a transgene product is delivered to a subject’s spinal cord by administering a recombinant neurotrophic viral vector containing the transgene to the brain. The viral vector delivers the transgene to a region of the brain which is susceptible to infection by the virus and which expresses the encoded recombinant viral gene product. Also provided are compositions for delivery of a transgene product to a subject’s spinal cord by administering a recombinant neurotrophic viral vector containing the transgene to the subject’s brain.